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Abstract
Background: Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced
melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune
related adverse events (IrAEs).
Case presentation: Here we describe a patient treated with ipilimumab who experienced known IrAEs, including
hypophysitis, as well as a profound vision loss due to optic neuritis. There are rare reports of optic neuritis occurring
as an adverse event associated with ipilimumab treatment. Furthermore, the patient experienced multiple
complications from high dose steroids used to manage his IrAEs.
Conclusions: This case highlights the need for recognition of atypical immune mediated processes associated with
newer checkpoint inhibitor therapies including ipilimumab.
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Background
Until recently, there were limited treatment options for
patients with advanced stage melanoma. In 2011, the
United States Food and Drug Association approved two
new treatments for advanced, unresectable melanoma -
the antagonist cytotoxic T-lymphocyte antigen 4
(CTLA-4) antibody, ipilimumab, and the targeted BRAF
inhibitor, vemurafenib. These new medications have dem-
onstrated significant benefits in overall survival [1–3].
Since then, additional therapies have been approved for
the treatment of advanced stage melanoma, both targeted
therapies [4–8] and immunotherapies, including the newly
FDA approved antagonist programmed cell death pro-
tein 1 (PD-1) antibodies, pembrolizumab and nivolu-
mab [9–12]. Immuno-oncology is a growing field in the
treatment of not only melanoma, but also other solid
tumors, such as non-small cell lung and renal cell cancer
[13]. These new treatments demonstrate improved and
durable responses, but have unique, immune-related side
effects which require prompt recognition and manage-
ment distinct from traditional cytotoxic chemotherapies.
Ipilimumab is a human monoclonal antibody directed
against CTLA-4. In the normal immune system, CTLA-4
downregulates activation of T-cells in hosts by interaction
with a co-receptor on the antigen presenting cell. Antag-
onism of CTLA-4 with ipilimumab therefore blocks co-
receptor interaction leading to activation of the innate
immune system, stimulating an immune response against
melanoma tumor cells [14]. It is well understood that
treatment with ipilimumab can result in a number of
immune related adverse events (IrAEs), felt to be the
result of cross-reactive tissue damage by activated T-
cells [15, 16]. Most IrAEs generally respond and resolve
with steroid treatment for several weeks or longer.
However, there are cases of IrAEs refractory to steroids
that require additional immunosuppressive interven-
tions, including intravenous immunoglobulin (IVIG) and
Infliximab [17–19]. The most common immune-related
side effects from treatment with ipilimumab include: colitis
- causing diarrhea, endocrinopathies - such as hypophysitis
and hypothyroidism, hepatitis, and dermatitis [20–25].
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Ophthalmologic complications from ipilimumab therapy
are rare, occurring in less than 1 % of patients, but generally
manifest as uveitis [26–28] with symptoms of blurred
vision, decreased visual acuity, dry eyes, pain, and photo-
phobia [28, 29]. An association of colitis with uveitis in pa-
tients has been reported [28]. Thyroid like orbitopathy
[16, 30–33] and ocular inflammation involving choroid
and retina [34–36] have also been reported. Optic neuritis,
which involves inflammation of the optic nerve is associ-
ated with a number of conditions including multiple scler-
osis and autoimmune disorders. Several biologic agents,
(especially tumor necrosis factor (TNF)-alpha inhibitors
like infliximab, etanercept, and adalimumab) have been
associated with optic neuritis [15]. Optic neuritis was
recently described in association with ipilimumab treat-
ment [33, 37]. We report here a patient who demonstrated
multiple immune-related adverse events including panhy-
popituitarism and optic neuritis, resulting in monocular
blindness, after undergoing treatment with ipilimumab.
Moreover, treatment of the immune-related side effects
with high dose steroids induced a catatonic depression
requiring electroconvulsive therapy (ECT).
Case presentation
A 53-year-old man was initially diagnosed with melanoma
of the left forearm: nodular melanoma, Breslow thickness
2.4 mm, at least Clark level IV, mitotic rate of 2-4/mm2,
no lymphovascular or perineural invasion, and no regres-
sion, ulceration, or satellitosis. He underwent wide local
excision and sentinel lymph node biopsy with one lymph
node with metastatic melanoma (microscopic metastases
with 2 foci <1 mm) and no additional involved lymph
nodes on completion lymph node dissection of the left
axilla. He was followed with close observation and did not
receive adjuvant therapy. The patient had consented to
an institutional melanoma registry for prospective ob-
servation and data collection which was approved by
the Institutional Review Board at the University of
Pennsylvania. Approximately one and half years later,
he presented with recurrence of his melanoma with
right groin lymph node involvement and bilateral small
lung metastases, BRAF V600 wild-type. He was treated
with temozolomide and sorafenib for six cycles with initial
stability of disease, then subsequent progression. During
this treatment, he was diagnosed with a pulmonary em-
bolus and received enoxaparin for anticoagulation. He was
then treated with carboplatin and paclitaxel for 11 cycles.
He initially tolerated treatment well and had stable disease
for a period of time; however, he subsequently experienced
disease progression and developed intolerable peripheral
neuropathy. He then participated in a clinical trial for
compassionate use of ipilimumab (prior to FDA approval)
a year and a half after initial disease recurrence. He
received ipilimumab at 3 mg/kg every 3 weeks for three
doses. He developed a rash (Grade 2) and intermittent
diarrhea (Grade 1) after his first dose of ipilimumab, both
of which were managed with supportive therapy, and did
not require anti-TNFalpha treatment. Nine weeks after
initiation of ipilimumab, he reported new headaches.
Given concern for possible hypophysitis, serum hormone
levels were evaluated and found to be abnormal – cortisol
−1.8 mcg/dl (6–19 mcg/dl), follicle-stimulating hormone
(FSH)-16.1 mIU/ml (1.5-12.4 mIU/ml), luteinizing
hormone (LH)-6.3 mIU/ml (1.7-8.6 mIU/ml), thyroid-
stimulating hormone (TSH)-0.07 (0.27-4.2 mIU/ml), and
testosterone-24 ng/dL (280–800 ng/dL). Magnetic reson-
ance imaging (MRI) of the brain confirmed inflammation
and edema of the pituitary gland consistent with a diagno-
sis of hypophysitis (Fig. 1). The fourth dose of ipilimumab
was held and prednisone 1 mg/kg/day, testosterone re-
placement, and thyroid hormone replacement were initi-
ated. His headaches resolved with steroid treatment.
He presented 4 months after initiation of ipilimumab
with shortness of breath and acute vision loss in his left
eye while on prednisone taper (40 mg daily) and thera-
peutic enoxaparin. Work up revealed a new small pul-
monary embolus. Ophthalmological examination revealed
no light perception vision in the left eye along with a left
afferent pupillary defect, optic nerve swelling, and retinal
whitening (Table 1). MRI of the brain and orbits, magnetic
resonance angiogram (MRA) of the cerebrovascular sys-
tem, carotid dopplers and an echocardiogram with bubble
study were unremarkable without evidence of brain or or-
bital metastases. Neuro-ophthalmic evaluation revealed
findings consistent with an ophthalmic artery occlusion.
The vision in his left eye remained at no light perception
and he continued on a steroid taper and his enoxaparin
was increased to twice daily dosing.
Five months after the initiation of ipilimumab, he de-
scribed blurred vision in his right eye along with postural
amaurosis. Ophthalmologic examination was notable for
visual acuity of 20/50 in the right eye with associated right
eye decreased color vision, visual field constriction, and
optic disc swelling; left eye vision remained no light per-
ception (Fig. 2). He was admitted to the hospital and
work-up included a normal head computed tomography
(CT) scan, brain MRI and magnetic resonance venography
(MRV). Two lumbar punctures were performed and re-
vealed cerebrospinal fluid (CSF) with elevated white blood
cells (WBC) (lymphocytic predominance) and protein, but
negative for malignancy or infection (Table 1). He was
continued on enoxaparin for a possible embolic or throm-
botic etiology of visual loss. The elevated CSF white blood
cells and protein raised concern for an inflammatory optic
neuropathy and aseptic meningitis, prompting treatment
with methylprednisolone one gram intraveneously (IV)
daily for three doses followed by an increased prednisone
dose. The patient reported subjective improvement in his
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right eye vision and the optic disc swelling improved.
However, three days following his last dose of methylpred-
nisolone, the vision in his right eye worsened and he de-
veloped a headache. He was readmitted to the hospital
and repeat MRI of the brain and orbits demonstrated cir-
cumferential enhancement of the right greater than left
intraorbital optic nerves (highlighted by arrows) suggestive
of optic neuritis (Fig. 3). MRA of the cerebrovascular sys-
tem did not demonstrate any significant arterial stenoses.
Repeat lumbar puncture demonstrated elevated WBCs
and protein and was negative for infection or malignancy.
The enhancement of the optic nerve and the noninfec-
tious inflammatory CSF findings suggested an immune-
mediated optic neuritis related to ipilimumab. He received
five days of IV methylprednisolone and the vision in his
right eye stabilized. He was discharged on a prednisone
taper, but had a third recurrence of blurred vision in his
right eye, double vision, and headaches. He was readmit-
ted to the hospital for IV steroids and further evaluation.
His vision stabilized with intravenous methylprednisolone
250 mg every six hours for 10 days. Given multiple failed
attempts at steroid weaning, he was initiated on mycophe-
nolate mofetil 1000 mg twice daily and then successfully
transitioned to prednisone 100 mg daily without changes
in vision. He again had no evidence of brain metastasis
and stable inguinal lymphadenopathy on repeat imaging.
Fifteen months after the initiation of ipilimumab, he was
clinically stable on mycophenolate mofetil and a slow
prednisone taper; his ophthalmologic examination was
notable for visual acuities of 20/20 in the right eye, and no
light perception in the left eye; the right optic disc swelling
had resolved, and the left optic nerve remained atrophic.
He was again intolerant of further steroid taper with
recurrent right eye blurred vision prompting hospital re-
admission and another course of intravenous methylpred-
nisolone 250 mg every 6 h. During this stay, he received
five treatments with plasmapheresis. A lumbar puncture
performed during this hospital stay was negative for
malignancy or infection and he was discharged on myco-
phenolate mofetil 1000 mg twice daily and prednisone
80 mg daily (Table 1). At this time, his metastatic melan-
oma was slowly progressing with increasing lymphaden-
opathy and his visual acuity ranged from 20/20 to 20/40
in the right eye, and no light perception in the left eye. He
also experienced several adverse effects from high dose
steroids, including catatonic depression, severe decondi-
tioning, and steroid myopathy.
Seventeen months after initiation of ipilimumab, the
patient experienced increased fatigue, lightheadedness,
and multiple falls at home. Head imaging demonstrated
multiple hemorrhagic brain metastases. Anticoagulation
was stopped and an inferior vena cava filter was placed.
Four days later the patient was found to be obtunded.
Comfort measures were initiated and the patient passed
away shortly afterward.
Discussion
With the increased use of checkpoint inhibitors, antagonist
CTLA-4 and PD-1 and PDL-1 antibodies, and the growing
field of immuno-oncology, the recognition and treatment
of immune-related side effects is crucial. This case high-
lights several issues: a patient can develop multiple IrAEs,
IrAEs can develop while on steroid treatment, IrAEs can be
delayed in onset, steroid therapy alone may not be sufficient
to effect and maintain control of IrAEs, and the treatments
required for management of IrAEs (ie steroids, immuno-
suppressive therapy) may have significant adverse effects.
Most importantly, we highlight a rare complication of optic
neuropathy.
Initially, the patient’s left eye vision loss was thought
to be vascular in nature, given a new pulmonary em-
bolus, the acute onset of his vision loss, and the retinal
findings of optic disc swelling and retinal whitening in
the setting of ongoing treatment with high dose prednis-
one for previously diagnosed hypophysitis. The possibil-
ity of an ocular IrAE was discussed from the outset but
Fig. 1 MRI brain two months prior to onset of visual complaints, demonstrating enlargement and enhancement (arrows) of the pituitary gland
consistent with hypophysitis
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Table 1 Diagnostic Tests and Workup of Patient’s Vision Loss
Time after initial
ipilimumab treatment
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then prednisone 40 mg
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1 gram x 5 days, then
prednisone 100 mg daily,
tapered to 80 mg daily
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IV 1 gram daily
x 10 days, then
prednisone 100 mg
daily, mycophenolate
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neg
Cx neg Cx neg
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the presentation was not determined to be concordant.
Although it is possible that a vascular mechanism as the
result of drug effect is still possible, and there are rare
reports of vascular related issues, there is nothing defini-
tive to suggest this. Shortly thereafter, the second eye
then became affected in a fashion more typical of an in-
flammatory optic neuritis.
Importantly, these new and different visual complaints
in the right eye occurred despite full anti-coagulation
and prednisone therapy. The initial MRI of the brain
and orbits was unrevealing and the clinical findings in
the right eye were distinct from those previously identi-
fied in the left eye. However, repeat MRI imaging of the
orbits revealed bilateral subtle circumferential perineural
optic nerve enhancement suggestive of optic nerve in-
flammation. This feature, in conjunction with the nonin-
fectious inflammatory CSF, supported the diagnosis of
atypical optic neuritis from an immune-mediated
process. High dose steroid therapy stabilized the right
eye vision but the left eye vision never improved after
initial presentation, again supporting a probable vascular
cause for the left eye visual loss. This may or may not
have been secondary to an inflammatory/immune-medi-
ated process (ie, local thrombosis related to inflamma-
tion/vasculitis). Given intolerance of even small tapering
of steroids, mycophenolate mofetil was selected due to
its use in the treatment of other inflammatory/immune-
mediated optic neuropathies as well as for its possible
penetration into the CNS.
The patient’s visual loss in the right eye was not con-
sistent with an ischemic optic neuropathy as optic nerve
ischemia causes permanent visual impairment and is not
steroid dependent. Infectious or parainfectious optic
neuropathies, although possible in this immunosup-
pressed patient, were also felt to be unlikely due to an
extensive laboratory work up which was unremarkable.
This included negative cytomegalovirus (CMV), varicella
zoster virus (VZV), rapid plasma reagin (RPR), lyme and
bartonella titers. The patient never developed findings
suspicious for retinal metastases or paraneoplastic retin-
opathy. Finally, acute demyelinating optic neuritis was
considered in the differential given the enhancement of
the optic nerve seen on MRI. However, during a follow
up of approximately one and half years no additional or
new neurological complaints developed and multiple
MRI scans during this period were normal with no de-
myelinating lesions noted. Neuromyelitis optica (NMO)
antibodies were not ordered.
It is noteworthy that the visual symptoms developed
while on steroid therapy and 4 months after the last dose
of CTLA-4 blockade. Given treatment with ipilimumab ac-
companied by the well described immune related adverse
event of hypophysitis, it is reasonable to conclude that the
optic nerve involvement was also an immune-related ad-
verse event attributable to ipilimumab. Kaehler et. al. re-
ported a characteristic pattern of immune-mediated side
effects related to ipilimumab use, with some manifestations
[29, 38] occurring weeks following treatment.
Fig. 2 Fundus photos, taken after onset of right eye blurred vision,
demonstrating mild swelling of the right optic disc (left) and pallor of the
left optic disc (right)
Fig. 3 MRI orbits after onset of right eye vision loss, demonstrating subtle circumferential perineural enhancement of bilateral optic nerves,
demonstrated on axial and coronal views consistent with optic nerve inflammation (highlighted by the arrows)
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The immune mediated mechanism of action of these
side effects is unique to checkpoint blockade and, unlike
other drug-mediated side effects, is a T-lymphocyte (T
cell) mediated process. Moreover, it is thought that there
is loss of recognition of self-antigens and decreased self-
tolerance [39, 40], which then results in an autoimmune
response. Histologically, tissues affected by immune
responses (both antitumor and adverse events) after ipi-
limumab treatment demonstrate a T-cell infiltrate [29],
however multiple types of infiltrates have been observed
– neutrophilic, lymphocytic, and mixed neutrophilic and
lymphocytic infiltrates [26, 29]. The recommended ther-
apy for IrAEs involves suppression of T-cell function,
with steroids or other immunosuppressive agents, which
interestingly does not interfere with the anti-tumor
effect of ipilimumab [24]. This patient’s visual loss was
severe in one eye and recurred multiple times in the
other eye requiring many courses of steroids, plasma-
pheresis, IVIG, and mycophenylate mofetil.
Conclusion
This patient with metastatic melanoma developed hypo-
physitis related to treatment with ipilimumab, and
subsequently developed acute left vision loss and waxing
and waning vision loss of the right eye consistent with
an inflammatory optic neuritis attributed to CTLA-4
blockade. This case emphasizes a rare and refractory
IrAE. The recognition of immune-related adverse events
is not limited to oncologists, but extends to physicians
in other subspecialties that will be involved in the care
of patients receiving immune modulating therapies.
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